HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pop Mart (9992 HK) - 2025 High Growth Is a Done Deal, but How About 2026?

Pre-IPO Kayou - The Strength of Business Model and the Potential Risks Behind

Pre-IPO 52TOYS Development - The Business Model and the Concerns Behind

Pop Mart (9992 HK) - Core Reasons for High Growth and Performance Forecast

Kangji Medical (9997 HK) Privatization - The Cancellation Price Is Not Attractive

Equity Capital Markets

TOP TOY International Group / Equity Capital Markets

<ul>
<li>Relying on MINISO’s mature retail system, TOP TOY has achieved scale accumulation rapidly.Real challenge lies in whether it can continuously create "blockbuster proprietary IPs" and reduce reliance on licensing model.</li>
<li>Due to smaller revenue proportion of proprietary IPs/overseas revenue and lower profit margin, valuation of TOP TOY should be lower than Pop Mart, but would be higher than MINISO.</li>
<li>If based on 2025 forecast, valuation is RMB9.3-11.2 billion. So, post-money valuation of US$1.3 billion after Series A financing is not cheap. Valuation premium space after IPO may be lower-than-expected.</li>
</ul>


Relying on MINISO’s mature retail system, TOP TOY has achieved scale accumulation rapidly.Real challenge lies in whether it can continuously create "blockbuster proprietary IPs" and reduce reliance on licensing model.
Due to smaller revenue proportion of proprietary IPs/overseas revenue and lower profit margin, valuation of TOP TOY should be lower than Pop Mart, but would be higher than MINISO.
If based on 2025 forecast, valuation is RMB9.3-11.2 billion. So, post-money valuation of US$1.3 billion after Series A financing is not cheap. Valuation premium space after IPO may be lower-than-expected.


Pre-IPO TOP TOY International Group - The Industry, the Business and the Valuation Outlook